Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

L-Pgds but not H-Pgds deletion causes hypertension and accelerates thrombogenesis in mice.

Song WL, Ricciotti E, Liang X, Grosser T, Grant GR, FitzGerald GA.

J Pharmacol Exp Ther. 2018 Oct 10. pii: jpet.118.250936. doi: 10.1124/jpet.118.250936. [Epub ahead of print]

2.

Health-relevant phenotypes in the offspring of mice given CAR activators prior to pregnancy.

Dietrich K, Baumgart J, Eshkind L, Reuter L, Godtel-Armbrust U, Butt E, Musheev M, Marini F, More P, Grosser T, Niehrs C, Wojnowski L, Mathas M.

Drug Metab Dispos. 2018 Aug 28. pii: dmd.118.082925. doi: 10.1124/dmd.118.082925. [Epub ahead of print]

PMID:
30154105
3.

Weight-adjusted aspirin for cardiovascular prevention.

Theken KN, Grosser T.

Lancet. 2018 Aug 4;392(10145):361-362. doi: 10.1016/S0140-6736(18)31307-2. Epub 2018 Jul 17. No abstract available.

4.

Correction: Nonsteroidal anti-inflammatory drug choice and adverse outcomes in clopidogrel users: A retrospective cohort study.

Nam YH, Brensinger CM, Bilker WB, Leonard CE, Kasner SE, Grosser T, Li X, Hennessy S.

PLoS One. 2018 Jul 16;13(7):e0200982. doi: 10.1371/journal.pone.0200982. eCollection 2018.

5.

COX-2 mediates pro-tumorigenic effects of PKCε in prostate cancer.

Garg R, Blando JM, Perez CJ, Lal P, Feldman MD, Smyth EM, Ricciotti E, Grosser T, Benavides F, Kazanietz MG.

Oncogene. 2018 May 16. doi: 10.1038/s41388-018-0318-9. [Epub ahead of print]

PMID:
29765153
6.

Nonsteroidal anti-inflammatory drug choice and adverse outcomes in clopidogrel users: A retrospective cohort study.

Nam YH, Brensinger CM, Bilker WB, Leonard CE, Kasner SE, Grosser T, Li X, Hennessy S.

PLoS One. 2018 Mar 14;13(3):e0193800. doi: 10.1371/journal.pone.0193800. eCollection 2018. Erratum in: PLoS One. 2018 Jul 16;13(7):e0200982.

7.

Urinary Prostaglandin Metabolites: An Incomplete Reckoning and a Flush to Judgment.

Grosser T, Naji A, FitzGerald GA.

Circ Res. 2018 Feb 16;122(4):537-539. doi: 10.1161/CIRCRESAHA.118.312616. No abstract available.

PMID:
29449357
8.

Cyclooxygenase Inhibition: Pain, Inflammation, and the Cardiovascular System.

Grosser T, Theken KN, FitzGerald GA.

Clin Pharmacol Ther. 2017 Oct;102(4):611-622. doi: 10.1002/cpt.794. Epub 2017 Aug 17.

PMID:
28710775
9.

The Cardiovascular Pharmacology of Nonsteroidal Anti-Inflammatory Drugs.

Grosser T, Ricciotti E, FitzGerald GA.

Trends Pharmacol Sci. 2017 Aug;38(8):733-748. doi: 10.1016/j.tips.2017.05.008. Epub 2017 Jun 23. Review.

10.

Reply: Collapse of the Aspirin Empire: Is it Diabetic Gastroparesis or Cardioprotective Paresis?

Bhatt DL, Grosser T, Dong JF, Logan D, Jeske W, Angiolillo DJ, Frelinger AL 3rd, Liang J, Cryer B, Marathi U.

J Am Coll Cardiol. 2017 Jun 13;69(23):2879. doi: 10.1016/j.jacc.2017.03.599. No abstract available.

11.

An alter-centric perspective on employee innovation: The importance of alters' creative self-efficacy and network structure.

Grosser TJ, Venkataramani V, Labianca GJ.

J Appl Psychol. 2017 Sep;102(9):1360-1374. doi: 10.1037/apl0000220. Epub 2017 Apr 17.

PMID:
28414473
12.

Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.

Grosser T.

N Engl J Med. 2017 Apr 6;376(14):1389. doi: 10.1056/NEJMc1702534. No abstract available.

13.

Time for nonaddictive relief of pain.

Grosser T, Woolf CJ, FitzGerald GA.

Science. 2017 Mar 10;355(6329):1026-1027. doi: 10.1126/science.aan0088. Epub 2017 Mar 9. No abstract available.

PMID:
28280170
14.

Employees' responses to an organizational merger: Intraindividual change in organizational identification, attachment, and turnover.

Sung W, Woehler ML, Fagan JM, Grosser TJ, Floyd TM, Labianca GJ.

J Appl Psychol. 2017 Jun;102(6):910-934. doi: 10.1037/apl0000197. Epub 2017 Mar 9.

PMID:
28277723
15.

Microfluidic whole blood testing of platelet response to pharmacological agents.

Li R, Grosser T, Diamond SL.

Platelets. 2017 Jul;28(5):457-462. doi: 10.1080/09537104.2016.1268254. Epub 2017 Jan 19. Review.

16.

Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus.

Bhatt DL, Grosser T, Dong JF, Logan D, Jeske W, Angiolillo DJ, Frelinger AL 3rd, Lei L, Liang J, Moore JE, Cryer B, Marathi U.

J Am Coll Cardiol. 2017 Feb 14;69(6):603-612. doi: 10.1016/j.jacc.2016.11.050. Epub 2017 Jan 11.

17.

A broad-spectrum lipidomics screen of antiinflammatory drug combinations in human blood.

Mazaleuskaya LL, Lawson JA, Li X, Grant G, Mesaros C, Grosser T, Blair IA, Ricciotti E, FitzGerald GA.

JCI Insight. 2016 Aug 4;1(12). pii: e87031.

18.

Timing of expression of the core clock gene Bmal1 influences its effects on aging and survival.

Yang G, Chen L, Grant GR, Paschos G, Song WL, Musiek ES, Lee V, McLoughlin SC, Grosser T, Cotsarelis G, FitzGerald GA.

Sci Transl Med. 2016 Feb 3;8(324):324ra16. doi: 10.1126/scitranslmed.aad3305. Epub 2016 Feb 3.

19.

microRNA represses macromolecule.

Grosser T.

Blood. 2015 May 28;125(22):3365-6. doi: 10.1182/blood-2015-04-638353.

20.

Understanding multicellular function and disease with human tissue-specific networks.

Greene CS, Krishnan A, Wong AK, Ricciotti E, Zelaya RA, Himmelstein DS, Zhang R, Hartmann BM, Zaslavsky E, Sealfon SC, Chasman DI, FitzGerald GA, Dolinski K, Grosser T, Troyanskaya OG.

Nat Genet. 2015 Jun;47(6):569-76. doi: 10.1038/ng.3259. Epub 2015 Apr 27.

21.

Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs.

Li X, Fries S, Li R, Lawson JA, Propert KJ, Diamond SL, Blair IA, FitzGerald GA, Grosser T.

Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16830-5. doi: 10.1073/pnas.1406997111. Epub 2014 Nov 10.

22.

Myeloid Cell COX-2 deletion reduces mammary tumor growth through enhanced cytotoxic T-lymphocyte function.

Chen EP, Markosyan N, Connolly E, Lawson JA, Li X, Grant GR, Grosser T, FitzGerald GA, Smyth EM.

Carcinogenesis. 2014 Aug;35(8):1788-97. doi: 10.1093/carcin/bgu053. Epub 2014 Mar 3.

23.

Nanocarriers for vascular delivery of anti-inflammatory agents.

Howard MD, Hood ED, Zern B, Shuvaev VV, Grosser T, Muzykantov VR.

Annu Rev Pharmacol Toxicol. 2014;54:205-26. doi: 10.1146/annurev-pharmtox-011613-140002. Review.

24.

Response to letters regarding article, "Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin".

Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, Fitzgerald GA.

Circulation. 2013 Sep 17;128(12):e191. doi: 10.1161/CIRCULATIONAHA.113.004750. No abstract available.

PMID:
24043153
25.

Positive and negative workplace relationships, social satisfaction, and organizational attachment.

Venkataramani V, Labianca GJ, Grosser T.

J Appl Psychol. 2013 Nov;98(6):1028-39. doi: 10.1037/a0034090. Epub 2013 Aug 5. Erratum in: J Appl Psychol. 2014 May;99(3):450.

PMID:
23915428
26.

Microfluidic assay of platelet deposition on collagen by perfusion of whole blood from healthy individuals taking aspirin.

Li R, Fries S, Li X, Grosser T, Diamond SL.

Clin Chem. 2013 Aug;59(8):1195-204. doi: 10.1373/clinchem.2012.198101. Epub 2013 Apr 16.

27.

COX-2, the dominant source of prostacyclin.

Ricciotti E, Yu Y, Grosser T, Fitzgerald GA.

Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):E183. doi: 10.1073/pnas.1219073110. Epub 2013 Jan 4. No abstract available.

28.

Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin.

Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA.

Circulation. 2013 Jan 22;127(3):377-85. doi: 10.1161/CIRCULATIONAHA.112.117283. Epub 2012 Dec 4.

29.

Prostanoids and inflammatory pain.

Chen L, Yang G, Grosser T.

Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:58-66. doi: 10.1016/j.prostaglandins.2012.08.006. Epub 2012 Sep 3. Review.

PMID:
22981510
30.

Celecoxib pathways: pharmacokinetics and pharmacodynamics.

Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein TE.

Pharmacogenet Genomics. 2012 Apr;22(4):310-8. doi: 10.1097/FPC.0b013e32834f94cb. No abstract available.

31.

PharmGKB summary: very important pharmacogene information for PTGS2.

Thorn CF, Grosser T, Klein TE, Altman RB.

Pharmacogenet Genomics. 2011 Sep;21(9):607-13. doi: 10.1097/FPC.0b013e3283415515. No abstract available.

32.

Exogenous estrogen does not attenuate the association between rofecoxib and myocardial infarction in perimenopausal women.

Wade KC, Ellenberg JH, Grosser T, Brensinger CM, Kimmel SE, Hennessy S.

J Cardiovasc Pharmacol. 2011 Feb;57(2):194-200. doi: 10.1097/FJC.0b013e31820350d3.

33.

Deciphering the human platelet sheddome.

Fong KP, Barry C, Tran AN, Traxler EA, Wannemacher KM, Tang HY, Speicher KD, Blair IA, Speicher DW, Grosser T, Brass LF.

Blood. 2011 Jan 6;117(1):e15-26. doi: 10.1182/blood-2010-05-283838. Epub 2010 Oct 20.

34.

Fetal genotype for the xenobiotic metabolizing enzyme NQO1 influences intrauterine growth among infants whose mothers smoked during pregnancy.

Price TS, Grosser T, Plomin R, Jaffee SR.

Child Dev. 2010 Jan-Feb;81(1):101-14. doi: 10.1111/j.1467-8624.2009.01383.x.

PMID:
20331656
35.

Emotion recollected in tranquility: lessons learned from the COX-2 saga.

Grosser T, Yu Y, Fitzgerald GA.

Annu Rev Med. 2010;61:17-33. doi: 10.1146/annurev-med-011209-153129. Review.

PMID:
20059330
36.

Elective affinities--bioinformatic analysis of proteomic mass spectrometry data.

Li X, Pizarro A, Grosser T.

Arch Physiol Biochem. 2009 Dec;115(5):311-9. doi: 10.3109/13813450903390039. Review.

PMID:
19911947
37.

The translational therapeutics of prostaglandin inhibition in atherothrombosis.

Yu Y, Ricciotti E, Grosser T, Fitzgerald GA.

J Thromb Haemost. 2009 Jul;7 Suppl 1:222-6. doi: 10.1111/j.1538-7836.2009.03439.x. Review.

38.

Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy.

Grosser T.

J Investig Med. 2009 Aug;57(6):709-16. doi: 10.2310/JIM.0b013e3181b04d1f. Review.

PMID:
19602986
39.

The post-synaptic density of human postmortem brain tissues: an experimental study paradigm for neuropsychiatric illnesses.

Hahn CG, Banerjee A, Macdonald ML, Cho DS, Kamins J, Nie Z, Borgmann-Winter KE, Grosser T, Pizarro A, Ciccimaro E, Arnold SE, Wang HY, Blair IA.

PLoS One. 2009;4(4):e5251. doi: 10.1371/journal.pone.0005251. Epub 2009 Apr 16.

40.

Cyclooxygenase inhibitors repress vascular hyaluronan-synthesis in murine atherosclerosis and neointimal thickening.

Marzoll A, Nagy N, Wördehoff L, Dai G, Fries S, Lindner V, Grosser T, Fischer JW.

J Cell Mol Med. 2009 Sep;13(9B):3713-9. doi: 10.1111/j.1582-4934.2009.00736.x. Epub 2009 Mar 17.

41.

Prostanoids in health and disease.

Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA.

J Lipid Res. 2009 Apr;50 Suppl:S423-8. doi: 10.1194/jlr.R800094-JLR200. Epub 2008 Dec 17. Review.

42.

Complete downmodulation of P-selectin glycoprotein ligand in monocytes undergoing apoptosis.

Stampfuss JJ, Censarek P, Fischer JW, Kaber G, Rauch BH, Freidel K, Fischer U, Schulze-Osthoff K, Grosser T, Grandoch M, Schrör K, Weber AA.

Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1375-8. doi: 10.1161/ATVBAHA.108.166629. Epub 2008 May 1.

PMID:
18451333
43.

Analysis of the zebrafish proteome during embryonic development.

Lucitt MB, Price TS, Pizarro A, Wu W, Yocum AK, Seiler C, Pack MA, Blair IA, Fitzgerald GA, Grosser T.

Mol Cell Proteomics. 2008 May;7(5):981-94. doi: 10.1074/mcp.M700382-MCP200. Epub 2008 Jan 22.

44.

Alternative splicing of platelet cyclooxygenase-2 mRNA in patients after coronary artery bypass grafting.

Censarek P, Steger G, Paolini C, Hohlfeld T, Grosser T, Zimmermann N, Fleckenstein D, Schrör K, Weber AA.

Thromb Haemost. 2007 Dec;98(6):1309-15.

PMID:
18064329
45.

Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans.

Song WL, Wang M, Ricciotti E, Fries S, Yu Y, Grosser T, Reilly M, Lawson JA, FitzGerald GA.

J Biol Chem. 2008 Jan 11;283(2):1179-88. Epub 2007 Nov 8.

46.

Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis.

North TE, Goessling W, Walkley CR, Lengerke C, Kopani KR, Lord AM, Weber GJ, Bowman TV, Jang IH, Grosser T, Fitzgerald GA, Daley GQ, Orkin SH, Zon LI.

Nature. 2007 Jun 21;447(7147):1007-11.

47.

EBP, a program for protein identification using multiple tandem mass spectrometry datasets.

Price TS, Lucitt MB, Wu W, Austin DJ, Pizarro A, Yocum AK, Blair IA, FitzGerald GA, Grosser T.

Mol Cell Proteomics. 2007 Mar;6(3):527-36. Epub 2006 Dec 12.

48.

The pharmacology of selective inhibition of COX-2.

Grosser T.

Thromb Haemost. 2006 Oct;96(4):393-400. Review.

PMID:
17003913
49.

Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin.

American Gastroenterological Association, Wilcox CM, Allison J, Benzuly K, Borum M, Cryer B, Grosser T, Hunt R, Ladabaum U, Lanas A, Paulus H, Regueiro C, Sandler RS, Simon L.

Clin Gastroenterol Hepatol. 2006 Sep;4(9):1082-9. Epub 2006 Jul 31. No abstract available. Erratum in: Clin Gastroenterol Hepatol. 2006 Nov;4(11):1421. Dosage error in article text.

PMID:
16877048
50.

Lipoxygenase and prostaglandin G/H synthase cascades in cardiovascular disease.

Zhao L, Grosser T, Fries S, Kadakia L, Wang H, Zhao J, Falotico R.

Expert Rev Clin Immunol. 2006 Jul;2(4):649-58. doi: 10.1586/1744666X.2.4.649.

PMID:
20477620

Supplemental Content

Loading ...
Support Center